Cellectar Biosciences Files 8-K on Operations
Ticker: CLRB · Form: 8-K · Filed: Aug 13, 2024 · CIK: 1279704
| Field | Detail |
|---|---|
| Company | Cellectar Biosciences, Inc. (CLRB) |
| Form Type | 8-K |
| Filed Date | Aug 13, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: operations, financial-condition, sec-filing
Related Tickers: CLRB
TL;DR
Cellectar Bio filed an 8-K updating investors on financials and operations.
AI Summary
Cellectar Biosciences, Inc. filed an 8-K on August 13, 2024, reporting on its results of operations and financial condition, and including financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text.
Why It Matters
This filing indicates that Cellectar Biosciences is providing updates on its financial performance and condition to the SEC, which is important for investors to monitor the company's status.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of operational and financial information, not indicating any immediate or significant negative events.
Key Players & Entities
- Cellectar Biosciences, Inc. (company) — Registrant
- 100 Campus Drive, Florham Park, NJ, 07932 (location) — Principal executive offices address
- August 13, 2024 (date) — Date of earliest event reported
FAQ
What specific financial results are being reported in this 8-K?
The provided text of the 8-K filing does not contain specific financial figures or detailed results of operations.
What exhibits are included with this 8-K filing?
The filing indicates that financial statements and exhibits are included, but the specific list of exhibits is not detailed in the provided text.
When was Cellectar Biosciences, Inc. incorporated?
Cellectar Biosciences, Inc. was incorporated in Delaware.
What is the IRS Employer Identification Number for Cellectar Biosciences, Inc.?
The IRS Employer Identification Number for Cellectar Biosciences, Inc. is 04-3321804.
What was the former name of Cellectar Biosciences, Inc.?
The company was formerly known as NOVELOS THERAPEUTICS, INC. and COMMON HORIZONS INC.
Filing Stats: 453 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-08-13 06:45:19
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 per share CLRB The Nasdaq Capital M
Filing Documents
- tm2421529d2_8k.htm (8-K) — 26KB
- tm2421529d2_ex99-1.htm (EX-99.1) — 20KB
- 0001104659-24-088606.txt ( ) — 220KB
- clrb-20240813.xsd (EX-101.SCH) — 3KB
- clrb-20240813_lab.xml (EX-101.LAB) — 33KB
- clrb-20240813_pre.xml (EX-101.PRE) — 22KB
- tm2421529d2_8k_htm.xml (XML) — 3KB
02
Item 2.02. Results of Operations and Financial Condition. On August 13, 2024, we issued a press release announcing our financial results for the quarter ended June 30, 2024 and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Number Title 99.1 Press release dated August 13, 2024, titled "Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate Update" 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CELLECTAR BIOSCIENCES, INC. Date: August 13, 2024 By: /s/ Chad J. Kolean Name: Chad J. Kolean Title: Chief Financial Officer